Valuation: Newron Pharmaceuticals S.p.A.

Market Cap 171M 194M 162M 147M 275M 18.61B 278M 1.94B 749M 9.5B 728M 712M 30.58B P/E 2026 *
-6.17x
P/E 2027 * 230x
Enterprise Value 185M 210M 175M 159M 298M 20.15B 301M 2.1B 811M 10.29B 789M 772M 33.12B EV / Sales 2026 *
21.8x
EV / Sales 2027 * 4.75x
Free-Float
87.16%
Yield 2026 *
-
Yield 2027 * -
1 week-32.02%
Current month-37.30%
1 month-36.99%
3 months-38.30%
6 months-46.95%
Current year-67.64%
1 week 7.62
Extreme 7.62
11.5
1 month 7.62
Extreme 7.62
12.64
Manager TitleAgeSince
Chief Executive Officer 62 15/05/2012
Director of Finance/CFO - 01/01/2012
Chief Operating Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 62 15/05/2012
Director/Board Member - 01/04/2023
Director/Board Member - 17/04/2024
Change 5-day change 1-year change 3-year change Capi.($)
+6.32%-32.02% - - 195M
-0.03%+3.77%+12.35%+37.22% 49.06B
-0.90%-0.60%+48.56%+36.45% 44.6B
+0.18%+4.32%+336.71%+626.84% 43.24B
-1.13%-1.57%+8.85%+101.42% 41.73B
+0.34%-1.38%+5.53%+47.36% 29.93B
+0.33%-1.82%+23.55%+155.52% 17.19B
-1.86%+8.32%+6.41% - 15.35B
-3.20%-3.50%+25.33%+42.43% 15.54B
-1.25%-4.92% - - 15.11B
Average -0.87%+1.76%+58.41%+149.61% 30.19B
Weighted average by Cap. -0.65%+2.17%+73.11%+163.87%

Financials

2026 *2027 *
Net sales 8.49M 9.62M 8.03M 7.28M 13.65M 923M 13.79M 96.34M 37.13M 471M 36.11M 35.33M 1.52B 39.86M 45.17M 37.72M 34.21M 64.13M 4.33B 64.76M 452M 174M 2.21B 170M 166M 7.12B
Net income -29.99M -33.99M -28.38M -25.74M -48.25M -3.26B -48.73M -340M -131M -1.67B -128M -125M -5.36B -1.96M -2.22M -1.85M -1.68M -3.15M -213M -3.18M -22.2M -8.56M -109M -8.32M -8.14M -349M
Net Debt 14.21M 16.1M 13.44M 12.19M 22.86M 1.55B 23.09M 161M 62.16M 789M 60.46M 59.15M 2.54B 18.13M 20.55M 17.16M 15.56M 29.17M 1.97B 29.46M 206M 79.32M 1.01B 77.15M 75.47M 3.24B
Logo Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals SpA is an Italy-based company operating in the medical research sector. It is a biopharmaceutical company focused on the research, development, and commercialization of therapies for disorders of the central and peripheral nervous system (CNS). The Company specializes in neurological and psychiatric diseases, including schizophrenia and Parkinson’s disease. Its activities include drug discovery, clinical development, regulatory approval processes, and strategic licensing and commercialization partnerships with pharmaceutical companies worldwide. The Company has built a pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization, such as evenamide, safinamide and ralfinamide. Newron Pharmaceuticals SpA operates at global level.
Employees
-
Date Price Change
29/09/26 CHF 8.240 +6.32%
28/09/26 CHF 7.750 -27.02%
25/09/26 CHF 10.62 -1.76%
24/09/26 CHF 10.81 -4.00%
23/09/26 CHF 11.26 +2.36%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.058EUR
Average target price
50.62EUR
Spread / Average Target
+528.23%

Quarterly revenue - Rate of surprise